Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Device Market Looks Set To Gain In 2013 As Health Care Reforms Favor Diagnostics

This article was originally published in PharmAsia News

Executive Summary

China’s medical device market is posed to overtake France as the third largest by 2020 and pull even domestically with pharmaceuticals in coming years as government health care reforms put emphasis on diagnostics and prevention.

You may also be interested in...



J&J Opens Device R&D Center In China For Growing Rural Market

SHANGHAI - Johnson & Johnson and its device company in China Johnson & Johnson Medical (Suzhou) Ltd. will open a new innovation center in Suzhou to develop medical devices and diagnostic products for emerging markets in Asia

Zimmer Looks To Score Big In Chinese Orthopedic Market With Beijing Montagne Acquisition

U.S.-listed orthopedic device maker Zimmer Inc. says its latest overseas purchase of Beijing Montagne Medical Device Co. Ltd., gives it greater marketing access to the Chinese orthopedic implant market, growing at an estimated 15 percent annually, and a manufacturing base to compete with rivals already in the market

CROs at risk from China's new inventor regulation?

China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC083468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel